Official Positions for FRAX® Clinical Regarding Rheumatoid Arthritis

被引:32
|
作者
Broy, Susan B. [1 ]
Tanner, S. Bobo [2 ]
机构
[1] Chicago Med Sch, Rosalind Franklin Sch Med, N Chicago, IL USA
[2] Vanderbilt Univ, Med Ctr, Div Rheumatol & Allergy, Nashville, TN USA
基金
英国医学研究理事会;
关键词
Rheumatoid arthritis; osteoporosis; osteoporotic fracture; vertebral fracture; fracture risk; FRAX; BONE-MINERAL DENSITY; VERTEBRAL DEFORMITIES; RISK-FACTORS; FRACTURE RISK; INFLAMMATORY MARKERS; JAPANESE WOMEN; HIP-FRACTURES; OSTEOPOROSIS; ASSOCIATIONS; VARIABLES;
D O I
10.1016/j.jocd.2011.05.012
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Rheumatoid arthritis is the only secondary cause of osteoporosis that is considered independent of bone density in the FRAX (R) algorithm. Although input for rheumatoid arthritis in FRAX (R) is a dichotomous variable, intuitively, one would expect that more severe or active disease would be associated with a greater risk for fracture. We reviewed the literature to determine if specific disease parameters or medication use could be used to better characterize fracture risk in individuals with rheumatoid arthritis. Although many studies document a correlation between various parameters of disease activity or severity and decreased bone density, fewer have associated these variables with fracture risk. We reviewed these studies in detail and concluded that disability measures such as HAQ (Health Assessment Questionnaire) and functional class do correlate with clinical fractures but not morphometric vertebral fractures. One large study found a strong correlation with duration of disease and fracture risk but additional studies are needed to confirm this. There was little evidence to correlate other measures of disease such as DAS (disease activity score), VAS (visual analogue scale), acute phase reactants, use of non-glucocorticoid medications and increased fracture risk. We concluded that FRAX (R) calculations may underestimate fracture probability in patients with impaired functional status from rheumatoid arthritis but that this could not be quantified at this time. At this time, other disease measures cannot be used for fracture prediction. However only a few, mostly small studies addressed other disease parameters and further research is needed. Additional questions for future research are suggested.
引用
收藏
页码:184 / 189
页数:6
相关论文
共 50 条
  • [41] DIFFERENCE OF CLINICAL IMPLICATION REGARDING THE NUMBERS OF AUTOANTIBODIES AT PRESENTATION IN KOREAN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS
    Pyo, J. Y.
    Mun, C. -H.
    Jung, S. M.
    Lee, S. W.
    Song, J.
    Lee, S. K.
    Park, Y. B.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 580 - 580
  • [42] SERUM RANKL AND FRACTURE RISK USING FRAX TOOL IN POSTMENOPAUSAL RHEUMATOID ARTHRITIS PATIENTS
    Nasef, S. I.
    Omar, H. H.
    Abdalla, H. M.
    OSTEOPOROSIS INTERNATIONAL, 2016, 27 : S247 - S248
  • [43] FRACTURE RISK ASSESSMENT (FRAX) IN PATIENTS WITH RHEUMATOID ARTHRITIS IN THERAPY WITH ANTI-TNFα
    Anghel, D.
    Otlocan, L.
    Negru, M. M.
    Busuioc, E.
    Bursuc, R.
    Smedescu, V.
    Manolache, A.
    Jurcut, C.
    OSTEOPOROSIS INTERNATIONAL, 2019, 30 : S400 - S400
  • [44] RELATION BETWEEN FRAX INDEX AND ACPA SERUM LEVEL IN PREMENOPAUSAL RHEUMATOID ARTHRITIS PATIENTS
    Hassan, M. M.
    Aboeladl, N. A.
    Eltawab, S. S.
    OSTEOPOROSIS INTERNATIONAL, 2018, 29 : S155 - S155
  • [45] HOW DOES RHEUMATOID ARTHRITIS IMPACT FRAX BASED ESTIMATES OF MOF: A NARRATIVE REVIEW?
    Ebrahimiarjestan, M.
    Yang, L.
    E, E.
    Wang, T.
    Carey, J. J.
    Whelan, B.
    Silke, C.
    O'sullivan, M.
    Gsel, A.
    Brennan, A.
    Dempsey, M.
    Yu, M.
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2023, 35 : S398 - S399
  • [46] Validating the FRAX Score in a US Population-Based Study of Patients with Rheumatoid Arthritis
    Peterson, Madeline
    Crowson, Cynthia
    Myasoedova, Elena
    Amin, Shreyasee
    Davis, John
    Achenbach, Sara
    Kholsa, Sundeep
    Atkinson, Elizabeth
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 1138 - 1140
  • [47] International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions
    Lewiecki, E. Michael
    Gordon, Catherine M.
    Baim, Sanford
    Leonard, Mary B.
    Bishop, Nicholas J.
    Bianchi, Maria-Luisa
    Kalkwarf, Heidi J.
    Langman, Craig B.
    Plotkin, Horatio
    Rauch, Frank
    Zemel, Babette S.
    Binkley, Neil
    Bilezikian, John P.
    Kendler, David L.
    Hans, Didier B.
    Silverman, Stuart
    BONE, 2008, 43 (06) : 1115 - 1121
  • [48] Clinical Use of Trabecular Bone Score: The 2023 ISCD Official Positions
    Goel, Heenam
    Binkley, Neil
    Boggild, Miranda
    Chan, Wing P.
    Leslie, William D.
    Mccloskey, Eugene
    Morgan, Sarah L.
    Silva, Barbara C.
    Cheung, Angela M.
    JOURNAL OF CLINICAL DENSITOMETRY, 2024, 27 (01)
  • [49] The Official Positions of the International Society for Clinical Densitometry: Vertebral Fracture Assessment
    Rosen, Harold N.
    Vokes, Tamara J.
    Malabanan, Alan O.
    Deal, Chad L.
    Alele, Jimmy D.
    Olenginski, Thomas P.
    Schousboe, John T.
    JOURNAL OF CLINICAL DENSITOMETRY, 2013, 16 (04) : 482 - 488
  • [50] RHEUMATOID FACTORS ANTEDATING CLINICAL RHEUMATOID-ARTHRITIS
    AHO, K
    HELIOVAARA, M
    MAATELA, J
    TUOMI, T
    PALOSUO, T
    JOURNAL OF RHEUMATOLOGY, 1991, 18 (09) : 1282 - 1284